CHAMPIONS ONCOLOGY, INC. Operating Lease Cost
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Operating Lease Cost of $411.00 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. operating lease, cost for the quarter ending 2026-07-31 was $411.00K, a 6.80% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating lease, cost for the quarter ending 2026-04-30 was $447.00K, a 2.76% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating lease, cost for the quarter ending 2026-01-31 was $446.00K, a 2.76% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating lease, cost for the quarter ending 2025-10-31 was $445.00K, a 3.01% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating lease, cost for fiscal 2026 was $1.78M, a 2.77% increase from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. operating lease, cost for fiscal 2025 was $1.73M, a 2.98% increase from fiscal 2024.
- CHAMPIONS ONCOLOGY, INC. operating lease, cost for fiscal 2024 was $1.68M, a 7.28% increase from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. operating lease, cost for fiscal 2023 was $1.57M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-07-31 | $411.00K 10-Q · filed 2026-09-11 | $858.00K derived: sum of 2 quarters · filed 2026-09-11 | $1.30M derived: sum of 3 quarters · filed 2026-09-11 | $1.75M derived: sum of 4 quarters · filed 2026-09-11 |
| 2026-04-30 | $447.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $893.00K derived: sum of 2 quarters · filed 2026-07-27 | $1.34M derived: sum of 3 quarters · filed 2026-07-27 | $1.78M 10-K · filed 2026-07-27 |
| 2026-01-31 | $446.00K 10-Q · filed 2026-03-12 | $891.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.33M 10-Q · filed 2026-03-12 | $1.77M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-10-31 | $445.00K 10-Q · filed 2025-12-15 | $885.00K 10-Q · filed 2025-12-15 | $1.32M derived: sum of 3 quarters · filed 2026-09-11 | $1.75M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-07-31 | $441.00K 10-Q · filed 2026-09-11 | $876.00K derived: sum of 2 quarters · filed 2026-09-11 | $1.31M derived: sum of 3 quarters · filed 2026-09-11 | $1.74M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-04-30 | $435.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $869.00K derived: sum of 2 quarters · filed 2026-07-27 | $1.30M derived: sum of 3 quarters · filed 2026-07-27 | $1.73M 10-K · filed 2026-07-27 |
| 2025-01-31 | $434.00K 10-Q · filed 2026-03-12 | $866.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.29M 10-Q · filed 2026-03-12 | $1.72M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-10-31 | $432.00K 10-Q · filed 2025-12-15 | $861.00K 10-Q · filed 2025-12-15 | $1.28M derived: sum of 3 quarters · filed 2025-12-15 | $1.71M derived: sum of 4 quarters · filed 2025-12-15 |
| 2024-07-31 | $429.00K 10-Q · filed 2025-09-15 | $853.00K derived: sum of 2 quarters · filed 2025-09-15 | $1.27M derived: sum of 3 quarters · filed 2025-09-15 | $1.70M derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | $424.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | $846.00K derived: sum of 2 quarters · filed 2025-07-23 | $1.27M derived: sum of 3 quarters · filed 2025-07-23 | $1.68M 10-K · filed 2025-07-23 |
| 2024-01-31 | $422.00K 10-Q · filed 2025-03-17 | $842.00K derived: sum of 2 quarters · filed 2025-03-17 | $1.26M 10-Q · filed 2025-03-17 | |
| 2023-10-31 | $420.00K 10-Q · filed 2024-12-16 | $834.00K 10-Q · filed 2024-12-16 | ||
| 2023-07-31 | $416.00K 10-Q · filed 2024-09-13 | |||
| 2023-04-30 | $1.57M 10-K · filed 2024-07-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |